Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks. The data is seen as crucial for the future potential for its experimental next-generation obesity drug,

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Women who have quickly lost weight say strangers are now more likely to smile at them or strike up a conversation.

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. Three months after missing that target in its first phase 3 CagriSema trial,

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all these options stack up.